Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Pharma recommendation

- PMLiVE

Ipsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis

The life-long condition affects approximately 1,900 people in Scotland

- PMLiVE

Pfizer’s Elrexfio accepted by SMC to treat relapsed and refractory multiple myeloma

Approximately 475 new cases of the disease are diagnosed in Scotland every year

- PMLiVE

Boehringer and Lilly’s Jardiance granted MHRA approval to treat chronic kidney disease

Approximately 7.2 million people in the UK are affected by the long-term kidney condition

- PMLiVE

Eli Lilly and Boehringer’s Jardiance granted EC approval to treat chronic kidney disease

Approximately 47 million people in the EU are affected by the long-term kidney condition

- PMLiVE

AbbVie receives extended SMC recommendation for Rinvoq in rheumatoid arthritis patients

In Scotland, there are around 44,000 people living with the progressive autoimmune disease

- PMLiVE

Boehringer and Lilly’s Jardiance shows promise in phase 3 chronic kidney disease trial

Jardiance reduced disease progression and cardiovascular death by 28%

Biogen Idec building

SMC approves Biogen’s Vumerity for patients with multiple sclerosis

The new, at-home oral treatment has been developed for adults in Scotland living with relapsing-remitting multiple sclerosis

- PMLiVE

Boehringer Ingelheim/Lilly’s empagliflozin is first drug to show clear benefit in heart failure

Results presented at the European Society of Cardiology Congress from the phase 3 trial demonstrated a 27% drop in hospitalisation risk

AstraZeneca AZ

AZ’s Farxiga cuts risk of death in chronic kidney disease

Detailed results revealed at the European Society of Cardiology virtual congress

- PMLiVE

Boehringer/Lilly’s Jardiance hits the mark in pivotal heart failure trial

Drug reduced risk of death/hospitalisation in patients with and without diabetes

- PMLiVE

FDA says no to Lilly, Boehringer’s Jardiance in type 1 diabetes

Formally rejects extended use of SGLT2 inhibitor

- PMLiVE

FDA advisors say no to empagliflozin in type 1 diabetes

Approval of Boehringer, Lilly-partnered drug expansion looks unlikely

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links